Email this article 
CPD Articles
Quality use of medicines: The postmenopausal woman with osteoporosis
South African Family Practice | Vol 45, No 5 | a1944 |
DOI: https://doi.org/10.4102/safp.v45i5.1944
| ©
Submitted: 12 September 2011 | Published: 30 May 2003
Submitted: 12 September 2011 | Published: 30 May 2003
About the author(s)
Andy Gray, Department of Experimental and Clinical Pharmacology, Nelson R Mandela School of Medicine, University of Natal, South AfricaJulia Botha, Department of Experimental and Clinical Pharmacology, Nelson R Mandela School of Medicine, University of Natal, South Africa
Deon Hoffman, Department of Experimental and Clinical Pharmacology, Nelson R Mandela School of Medicine, University of Natal, South Africa
Full Text:
PDF (2MB)Abstract
Guidelines for the management of any condition suffer the ravages of time and can be challenged even by the publication of a single study. This may well apply to any guidelines that include hormone replacement therapy (HRT), such as the Osteoporosis Clinical Guideline published in 2000 by the South African Medical Association. Nothing that 'reliable comparative data on the various drugs registered for the treatment of osteoporosis are not available', the Osteoporosis Working Group attempted to guide clinicians' drug choices.
Keywords
postmenopausal woman; osteoporosis
Metrics
Total abstract views: 1460Total article views: 1762